Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist peptide featuring a novel unimolecular design based on the 39-amino acid GIP sequence with engineered GLP-1R cross-reactivity. A C20 fatty diacid moiety linked via a linker at Lys20 enables albumin binding and once-weekly dosing pharmacokinetics. The dual agonism produces synergistic metabolic effects: GIP receptor activation enhances pancreatic beta-cell function and insulin sensitivity in adipose tissue, while GLP-1R activation mediates appetite suppression, gastric emptying delay, and glucose-dependent insulin secretion. The SURPASS and SURMOUNT clinical trial programs demonstrated superior glycemic control compared to all other tested agents, along with unprecedented body weight reductions of up to 22.5% in some cohorts. Research applications include studies on dual incretin signaling synergy, beta-cell preservation, adipose tissue insulin sensitivity, hepatic de novo lipogenesis inhibition, and cardiovascular risk biomarker modulation.<\/p>\n","protected":false},"excerpt":{"rendered":"
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist peptide featuring a novel unimolecular design based on the 39-amino acid GIP sequence with engineered GLP-1R cross-reactivity. A C20 fatty diacid moiety linked via a linker at Lys20 enables albumin binding and once-weekly dosing pharmacokinetics. The dual agonism produces synergistic metabolic effects: GIP receptor activation […]<\/p>\n","protected":false},"featured_media":84,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[17],"product_tag":[],"class_list":["post-85","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n